Oxford capital eis fund

    • About Us

      Learn more about us

      Careers

      See our current oppurtunities

      Team

      Meet our team

      EIS investment faqs

      FAQs

      See our frequently asked questions

      News

      See our latest news articles

      Contact Us

      Get in touch with us

Investor Login
Contact Us

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

Positive news from portfolio company Oxford BioTherapeutics – it has announced today that it has achieved another milestone with Boehringer Ingelheim for the progress of a second oncology drug candidate.

 

 

Interested in Building a portfolio of shares in the future of UK technology?

Choose an option below to request an information pack:

I’m an investor
I’m an adviser

Share Post: